Clinical Trial Update: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant therapy with a PD-1 antibody (toripalimab), GEMOX chemotherapy, and lenvatinib for resectable intrahepatic cholangiocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• Lenvatinib (lenvatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Cholangiocarcinoma, Intrahepatic | Phase 2 | Status: UNKNOWN